Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Antero Resources despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Antero Resources is expected to report quarterly earnings of $0.53 per share, reflecting an 8.6% decrease year-over-year [3]. - Revenue projections stand at $1.31 billion, indicating a 12% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 23.96% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [9][10]. - Antero Resources currently holds a Zacks Rank of 3, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Antero Resources was expected to earn $0.22 per share but only achieved $0.15, resulting in a -31.82% surprise [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Conclusion - Antero Resources does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding the stock ahead of the earnings release [17].

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Ameren (AEE) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Februar ...

Financial Performance - Chubb reported $15.34 billion in revenue for the quarter ended December 2025, a year-over-year increase of 7.4% [1] - The EPS for the same period was $7.52, compared to $6.02 a year ago, representing a surprise of +13.89% over the consensus estimate of $6.60 [1] - The reported revenue exceeded the Zacks Consensus Estimate of $15.09 billion by +1.7% [1] Key Metrics - The combined ratio was 81.2%, better than the seven-analyst average estimate of 83.6% [4] - The loss and loss expense ratio was 54.3%, compared to the seven-analyst average estimate of 56.3% [4] - Net premiums written for North American Personal P&C Insurance were $1.72 billion, slightly below the average estimate of $1.75 billion, but showed a year-over-year change of +6.1% [4] - Total net premiums written for P&C were $11.31 billion, exceeding the average estimate of $11.05 billion, with a year-over-year increase of +7.7% [4] - Global Reinsurance net premiums written were $217 million, below the average estimate of $235.08 million, reflecting a year-over-year decrease of -3.1% [4] - Overseas General Insurance net premiums written were $3.81 billion, surpassing the average estimate of $3.71 billion, with a year-over-year increase of +10.8% [4] - Net premiums earned for Total P&C were $11.72 billion, exceeding the average estimate of $11.61 billion, representing a +6.2% change year-over-year [4] Stock Performance - Chubb's shares returned -1.3% over the past month, while the Zacks S&P 500 composite increased by +1.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

分组1 - Cabot reported quarterly earnings of $1.53 per share, exceeding the Zacks Consensus Estimate of $1.4 per share, but down from $1.76 per share a year ago, representing an earnings surprise of +9.36% [1] - The company posted revenues of $849 million for the quarter, missing the Zacks Consensus Estimate by 3.73%, and down from $955 million year-over-year [2] - Over the last four quarters, Cabot has surpassed consensus EPS estimates three times but has not beaten consensus revenue estimates [2] 分组2 - The stock has gained approximately 9.9% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] - The current consensus EPS estimate for the upcoming quarter is $1.66 on revenues of $891.24 million, and for the current fiscal year, it is $6.47 on revenues of $3.52 billion [7] - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 15% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - IAC reported a quarterly loss of $0.99 per share, significantly worse than the Zacks Consensus Estimate of $0.67, marking an earnings surprise of -248.32% [1] Financial Performance - IAC's revenues for the quarter ended December 2025 were $645.98 million, exceeding the Zacks Consensus Estimate by 0.83%, but down from $989.31 million a year ago [2] - Over the last four quarters, IAC has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] Stock Performance - IAC shares have declined approximately 5.3% since the beginning of the year, while the S&P 500 has gained 1.9% [3] Future Outlook - The company's earnings outlook will be crucial for stock performance, with current consensus EPS estimates at -$0.27 for the coming quarter and $0.45 for the current fiscal year [7] - The Zacks Rank for IAC is currently 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Context - The Diversified Operations industry, to which IAC belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Viewpoint - Rockwell Automation Inc. (ROK) is expected to report strong earnings growth in its first-quarter fiscal 2026 results, with an estimated EPS of $2.54, reflecting a 38.8% year-over-year increase, and sales projected at $2.09 billion, indicating a 10.9% rise from the previous year [1][5]. Earnings Estimates - The Zacks Consensus Estimate for ROK's earnings has increased by 1.2% over the past 60 days [1][5]. - The earnings surprise history shows ROK has consistently beaten estimates, with an average surprise of 12.3% over the last four quarters [2][3]. Earnings Prediction Model - The model indicates a likely earnings beat for ROK, supported by a positive Earnings ESP of +1.03% and a Zacks Rank of 2 (Buy) [4][6]. Segment Performance Expectations - The Intelligent Devices segment is expected to see a 20.2% year-over-year sales increase to $968 million, with an operating profit of $175 million, up 45.6% [11]. - The Software & Control segment is projected to achieve sales of $568 million, reflecting a 7.5% growth, with an operating profit of $168 million, indicating a 26% increase [12]. - The Lifecycle Services segment is anticipated to report sales of $521 million, a 4.7% decline, with an operating profit of $51 million, suggesting a 25.4% decrease [13]. Market Context - ROK's stock has performed well, increasing by 60.9% over the past year, outperforming the industry average of 35.7% [14].

Core Insights - Bunge Global SA (BG) is set to report its fourth-quarter 2025 results on February 4, with projected sales of $22 billion, reflecting a 62.5% year-over-year growth, while earnings per share (EPS) are expected to decline by 14.6% to $1.82 [1][5]. Financial Performance - The Zacks Consensus Estimate for BG's fourth-quarter sales is $22 billion, indicating a significant increase of 62.5% compared to the same quarter last year [1][5]. - The consensus estimate for earnings is $1.82 per share, which represents a year-over-year decline of 14.6% [1][5]. - Earnings estimates have decreased by 4.2% over the past 60 days [1]. Earnings Surprise History - Bunge has outperformed the consensus estimate in three of the last four quarters, with an average surprise of 11.75% [2][3]. Earnings ESP and Zacks Rank - The Earnings ESP for Bunge is currently -2.85%, and it holds a Zacks Rank of 3 (Hold), indicating that the model does not predict a definitive earnings beat this time [6][7]. Factors Influencing Q4 Performance - The fourth-quarter performance is expected to benefit from the Viterra acquisition, completed in July 2025, which has strengthened Bunge's global agricultural network and expanded its reach across major crops [7]. - The Soybean Processing and Refining segment is anticipated to show higher margins and processed volumes due to increased production capacity in Argentina [9]. - The Softseed Processing and Refining segment is also expected to improve, driven by higher average margins and contributions from Viterra's assets [10]. - In the Grain Merchandising and Milling segment, higher contributions from wheat milling and the sugar business are expected, although softer global wheat and corn merchandising may offset some gains [12]. Corporate Expenses - An increase in corporate expenses is anticipated, primarily due to the Viterra acquisition and performance-based compensation [13]. Stock Performance - Bunge's shares have increased by 51.9% over the past year, significantly outperforming the industry average growth of 2.9% [14].

Wall Street expects a year-over-year decline in earnings on lower revenues when Ford Motor Company (F) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for CVS Health despite higher revenues, with a focus on how actual results will compare to estimates [1] Earnings Expectations - CVS Health is expected to report quarterly earnings of $0.99 per share, reflecting a year-over-year decrease of 16.8% [3] - Revenue projections stand at $103.13 billion, indicating a 5.5% increase from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 0.1% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for CVS Health is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.38% [12] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - CVS Health currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - CVS Health has consistently beaten consensus EPS estimates, achieving this in the last four quarters [14] - In the last reported quarter, CVS Health exceeded expectations by delivering earnings of $1.60 per share against an expected $1.36, resulting in a surprise of +17.65% [13] Market Reaction - The stock price may increase if earnings exceed expectations, while a miss could lead to a decline [2] - Other factors beyond earnings results may also influence stock movement, highlighting the complexity of market reactions [15]

Core Viewpoint - The Southern Company (SO) has shown mixed performance in the market, with recent quarterly results exceeding expectations, but overall underperformance compared to broader indices and sector ETFs [2][5][6]. Financial Performance - The Southern Company reported total operating revenue of $7.8 billion for Q3, marking a 7.5% year-over-year increase and exceeding consensus estimates by 3.7% [5]. - Adjusted EPS for the same period rose 11.9% year-over-year to $1.60, surpassing analyst estimates by 6.7% [5]. - For the current fiscal year ending in December, analysts project SO's EPS to grow 5.9% year-over-year to $4.29 [6]. Market Comparison - Over the past 52 weeks, SO shares have gained 5.1%, while the S&P 500 Index has increased by 15.5% [2]. - SO has also underperformed compared to the State Street Utilities Select Sector SPDR ETF (XLU), which rose 9.5% in the same timeframe [3]. Analyst Ratings and Price Targets - Among 24 analysts covering SO, the consensus rating is a "Hold," with five "Strong Buy," one "Moderate Buy," 15 "Hold," and three "Strong Sell" ratings [6]. - RBC Capital analyst Stephen D'Ambrisi maintained a "Sector Perform" rating and raised the price target to $105, indicating a potential upside of 19.1% from current levels [7]. - The mean price target of $96.78 suggests a 9.7% premium from SO's current price, while the highest target of $108 indicates a potential upside of 22.5% [7].